Incidental Diagnosis of Leptomeningeal Disease in Breast Cancer with Brain Metastases- a Case Report with Review of Literature
DOI:
https://doi.org/10.30683/1927-7229.2025.14.08Keywords:
HER2-positive breast cancer, Leptomeningeal metastasis, Brain metastases, CSF cytology, MR spectroscopy, Intrathecal therapy, CNS involvement, ctDNA, Trastuzumab, Craniospinal irradiationAbstract
Background: Breast cancer is the most common malignancy in women worldwide, with 2.3 million new cases and 6,70,000 deaths reported in 2022 (Globocan). Metastatic breast cancer affects up to 30% of patients, with brain metastases occurring in approximately 25%, especially among Human epidermal growth factor receptor 2 (HER2) positive subtypes. Leptomeningeal disease (LMD), the dissemination of tumor cells to the leptomeninges and cerebrospinal fluid (CSF), is an uncommon but devastating complication. Diagnosing LMD is often challenging due to nonspecific symptoms and overlapping imaging features with infectious or inflammatory conditions. CSF cytology remains the gold standard, though newer diagnostic techniques such as CSF-based circulating tumor DNA (ctDNA) are emerging.
Case Presentation: We report a previously treated case of a 42-year-old premenopausal woman with HER2-positive, estrogen and progesterone receptor-negative, metastatic breast cancer, who presented with acute onset of altered sensorium, fever, and irritability. Magnetic Resonance Imaging (MRI) brain showed multiple enhancing lesions in the cerebral hemispheres, cerebellum, midbrain, and thalami, with surrounding edema. MR spectroscopy demonstrated reduced choline and elevated lipid-lactate peaks, initially suggesting an infective etiology, however, CSF cytology revealed malignant cells, with immunohistochemistry positive for GATA3 and PanCK, confirming leptomeningeal metastases of breast origin. She was planned for whole brain radiotherapy (WBRT) and intrathecal methotrexate.
Conclusion: This case highlights the diagnostic challenges of LMD in HER2-positive breast cancer. Radiological and spectroscopy findings may mimic infectious processes, especially in tuberculosis-endemic regions. In ambiguous cases, reliance on CSF cytology is crucial, and adjunctive molecular diagnostics like ctDNA may further enhance diagnostic yield. Leptomeningeal metastasis, though underdiagnosed, has significant therapeutic implications. Newer HER2-directed intrathecal therapies, advanced radiotherapy techniques such as craniospinal irradiation with helical tomotherapy or proton therapy, and evolving strategies for CSF drug delivery offer promising avenues for treatment. A high index of suspicion and early CSF evaluation can lead to timely diagnosis and potentially improved survival outcomes in this difficult to treat subset.
References
[1] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clinicians 2024; 74(3): 229-63.
[2] Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B. Brain metastasis in breast cancer: a comprehensive literature review. J Neurooncol 2016; 127(3): 407-14.
[3] Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, et al. Metastatic Behavior of Breast Cancer Subtypes. JCO 2010; 28(20): 3271-7.
[4] Pieńkowski T, Zielinski CC. Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. Annals of Oncology 2010; 21(5): 917-24.
[5] Distefano A, Yap HY, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer 1979; 44(5): 1913-8.
[6] Franzoi MA, Hortobagyi GN. Leptomeningeal carcinomatosis in patients with breast cancer. Critical Reviews in Oncology/Hematology 2019; 135: 85-94.
[7] Leyland-Jones B. Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Central Nervous System Metastases. JCO 2009; 27(31): 5278-86.
[8] Fink K, Fink J. Imaging of brain metastases. Surg Neurol Int 2013; 4(5): 209.
[9] Roy-O’Reilly MA, Lanman T, Ruiz A, Rogawski D, Stocksdale B, Nagpal S. Diagnostic and Therapeutic Updates in Leptomeningeal Disease. Curr Oncol Rep 2023; 25(8): 937-50.
[10] Gupta RK, Jobanputra KJ, Yadav A. MR Spectroscopy in Brain Infections. Neuroimaging Clinics of North America 2013; 23(3): 475-98.
[11] Sze G, Soletsky S, Bronen R, Krol G. MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. American Journal of Roentgenology 1989; 153(5): 1039-49.
[12] Dietemann JL, Correia Bernardo R, Bogorin A, Abu Eid M, Koob M, Nogueira Th, et al. Les prises de contraste méningées normales et pathologiques en IRM. Journal de Radiologie 2005; 86(11): 1659-83.
[13] Di WY, Chen YN, Cai Y, Geng Q, Tan YL, Li CH, et al. The diagnostic significance of cerebrospinal fluid cytology and circulating tumor DNA in meningeal carcinomatosis. Front Neurol [Internet] 2023 Mar 3 [cited 2025 Jul 25]; 14.
[14] Li X, Zhang Y, Ding J, Wang M, Li N, Yang H, et al. Clinical significance of detecting CSF-derived tumor cells in breast cancer patients with leptomeningeal metastasis. Oncotarget 2018; 9(2): 2705-14.
[15] Ballester LY, Glitza Oliva IC, Douse DY, Chen MM, Lan C, Haydu LE, et al. Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease. Journal of Neuropathology & Experimental Neurology 2018; 77(7): 628-35.
[16] Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun [Internet] 2017 Nov 6 [cited 2025 Jul 25]; 8(1). Available from: https://www.nature.com/articles/s41467-017-00965-y
[17] Tsao MN, editor. Whole brain radiotherapy for the treatment of multiple brain metastases. In: Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2006 [cited 2025 Jul 25].
[18] Anat J. Proceedings BlackwellScience,Ltd of the Anatomical Society of Great Britain and Ireland 2002;
[19] Gerstner ER, Fine RL. Increased Permeability of the Blood-Brain Barrier to Chemotherapy in Metastatic Brain Tumors: Establishing a Treatment Paradigm. JCO 2007 Jun 1; 25(16): 2306-12.
[20] Dobrogowska DH, Lossinsky AS, Tarnawski M, Vorbrodt AW. Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor. J Neurocytol 1998; 27(3): 163-73.
[21] Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer. Clinical Cancer Research 2010 Dec 1; 16(23): 5664-78.
[22] Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 2009; 100(6): 894-900.
[23] Montemurro F, Delaloge S, Barrios CH, Wuerstlein R, Anton A, Brain E, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Annals of Oncology 2020; 31(10): 1350-8.
[24] Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 2020; 382(7): 597-609.
[25] Carausu M, Carton M, Darlix A, Pasquier D, Leheurteur M, Debled M, et al. Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database. ESMO Open 2021; 6(3): 100150.
[26] O’Brien BJ, Murthy RK, Berry DA, Singareeka Raghavendra A, Gule-Monroe M, Johnson JM, et al. Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results. JCO 2024; 42(16_suppl): 2018-2018.
[27] Mego M, Sycova-Mila Z, Obertova J, Rajec J, Liskova S, Palacka P, et al. Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis. The Breast 2011; 20(5): 478-80.
[28] Bartsch R, Jerzak KJ, Larrouquere L, Müller V, Le Rhun E. Pharmacotherapy for leptomeningeal disease in breast cancer. Cancer Treatment Reviews 2024; 122: 102653.
[29] Buszek SM, Chung C. Radiotherapy in Leptomeningeal Disease: A Systematic Review of Randomized and Non-randomized Trials. Front Oncol [Internet] 2019 Nov 15 [cited 2025 Jul 26]; 9.
[30] Harada H, Mitsuya K, Asakura H, Ogawa H, Onoe T, Kawashiro S, et al. Cranio-Spinal Irradiation for Leptomeningeal Carcinomatosis: A Pilot Study. International Journal of Radiation Oncology*Biology*Physics 2014; 90(1): S310.
[31] Yang TJ, Wijetunga NA, Yamada J, Wolden S, Mehallow M, Goldman DA, et al. Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. Neuro-Oncology 2021; 23(1): 134-43.
[32] Smith DL, Debeb BG, Diagaradjane P, Larson R, Kumar S, Ning J, et al. Prophylactic cranial irradiation reduces the incidence of brain metastasis in a mouse model of metastatic, HER2-positive breast cancer. Genes Cancer 2021; 12: 28-38.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Similar Articles
- Priyank A. Shenoy, Why is Immunohistochemical Detection of Metastasized Breast Cancer Cells in the Immunocompetent Host Not Always Easy? , Journal of Analytical Oncology: Vol. 7 No. 4 (2018)
- Guan Min Lai, Jen-Tsun Lin , Cheng-Shyong Chang , Metastatic Bone Marrow Tumors Manifested by Hematologic Disorders: Study of Thirty-Four Cases and Review of Literature , Journal of Analytical Oncology: Vol. 3 No. 4 (2014)
- Ravoori Harish Babu, Amritha Prabha Shankar, Geeta S. Narayanan, Ganesh M. Subramanya, B.R. Kiran Kumar, Association of Level III Axillary Lymph Node Positivity with Clinicopathological Characteristics in Breast Cancer , Journal of Analytical Oncology: Vol. 13 (2024)
- Joseph E. Udosen, John A. Ashindoitiang, Victor I.C. Nwagbara, Theophilus I. Ugbem, Joseph S. Ukam, Maurice E. Asuquo, Concurrent Plasma Cell Mastitis and Metastatic Breast Cancer a Rare Presentation of a Bilateral Disease: Case Report and Literature Review , Journal of Analytical Oncology: Vol. 13 (2024)
- Vu Hong Thang, Lambert Skoog, Nguyen Ba Duc, Ta Thanh Van, Edneia Tani , Cell Proliferation Measured by Ki67 Staining and Correlation to Clinicopathological Parameters in Operable Breast Carcinomas from Vietnamese and Swedish Patients , Journal of Analytical Oncology: Vol. 4 No. 2 (2015)
- Maria Caffo, Antonello Curcio, Roberta Laera, Valeria Barresi, Gerardo Caruso, Intracranial Dural Metastases and Diagnostic Misunderstandings , Journal of Analytical Oncology: Vol. 11 (2022)
- Javier Garde Noguera, Elena Evgenyeva, Mireia Gil Raga, Asunción Juárez Marroquí, Juan Manuel Gasent Blesa, Juan Laforga, Laia Bernet, Mónica Clemente Císcar, Carlos Camps Herrero, Antonio Llombart Cussac, Role of Primary Tumour Resection and Addition of Bevacizumab to Chemotherapy in the Management of Advanced Colorectal Cancer with Inoperable Metastasis: A Retrospective Analysis , Journal of Analytical Oncology: Vol. 2 No. 4 (2013)
- A. Piersigilli, A. D. Borowsky, Q. Chen, N.E. Hubbard , R.D. Cardiff , Current Concepts and New Insights from Mouse Models of Mammary Tumors on Epithelial Mesenchymal Transition and its Synergy with Mutant p53 , Journal of Analytical Oncology: Vol. 4 No. 4 (2015)
- Khan Anna, Chadha D. Vijayta, Emerging Role of 177Lu in Nuclear Oncology: A Brief Review , Journal of Analytical Oncology: Vol. 6 No. 4 (2017)
- Hassan Akbari, Farzad Taghizadeh Hesary, Laya Rahnar Nikoukar, Distribution of Breast Cancer Biomarkers by Age in Iran , Journal of Analytical Oncology: Vol. 6 No. 1 (2017)
You may also start an advanced similarity search for this article.